ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

ARGX Argen X SE

358,60
-4,50 (-1,24%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Argen X SE ARGX Euronext Ordinary Share
  Änderung Änderung % Aktuell Zeit
-4,50 -1,24% 358,60 17:40:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
364,00 357,10 368,80 358,60 363,10
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.5.202407:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16.4.202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27.3.202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26.3.202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26.3.202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07.3.202422:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29.2.202407:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26.2.202407:00GLOBEargenx to Present at Upcoming Investor Conferences
22.2.202407:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20.2.202407:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18.1.202407:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08.1.202407:00GLOBEargenx Highlights 2024 Strategic Priorities
02.1.202407:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20.12.202307:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28.11.202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16.11.202313:40GLOBEargenx Announces European Commission Approval of..
01.11.202307:00GLOBEargenx to Present at Upcoming Investor Conferences
31.10.202307:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24.10.202307:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21.9.202307:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15.9.202307:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30.8.202307:00GLOBEargenx to Present at Upcoming Investor Conferences
27.7.202307:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24.7.202322:30GLOBEargenx announces closing of global offering
20.7.202307:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19.7.202323:58GLOBEargenx announces full exercise of underwriters’ option to..
19.7.202303:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17.7.202322:01GLOBEargenx announces launch of proposed global offering
17.7.202307:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30.6.202315:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
21.6.202300:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20.6.202307:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31.5.202307:00GLOBEargenx to Present at Upcoming Investor Conferences

Kürzlich von Ihnen besucht

Delayed Upgrade Clock